查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600260

甲状腺癌药物市场：按药物类型、给药方法、分期、癌症类型、最终用户分类 - 全球预测 2025-2030

Thyroid Cancer Drugs Market by Drug Type (Chemotherapy Drugs, Hormone Therapy Drugs, Immunotherapy Drugs), Mode of Administration (Injectable Drugs, Intravenous Drugs, Oral Drugs), Stage of Disease, Cancer Type, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年甲状腺癌治疗市场价值为8.0601亿美元，预计到2024年将达到8.9096亿美元，复合年增长率为11.02%，到2030年将达到16.7577亿美元。

甲状腺癌药物市场范围包括专门用于治疗甲状腺癌的药物，例如小分子抑制剂、免疫疗法、放射性碘疗法和甲状腺荷尔蒙疗法。该领域对于解决未满足的医疗需求至关重要，因为甲状腺癌发病率的增加强调了对有效治疗方法的需求。这些药物主要由医疗专业人员在临床环境中应用，以治疗和治疗各种类型的甲状腺癌，包括乳头状癌、滤泡状癌、髓样癌和未分化癌。最终用途包括医院、肿瘤中心和专门的癌症治疗诊所。该市场的关键成长要素包括精准医学和标靶治疗的进步、研发投资的增加以及患者对有效治疗方案的认识和需求的提高。生物相似药的出现以及人工智慧在药物发现中的整合是一个潜在的机会，可以为更个人化的医疗和具有成本效益的治疗铺平道路。为了利用这些机会，製药公司必须投资强有力的研发计划和策略伙伴关係关係，以加速药物开发并简化监管核准。然而，该市场面临高昂的开发成本、严格的法律规范以及与甲状腺癌治疗相关的潜在副作用等限制。此外，与手术治疗方法的竞争也是一个问题，因为一些患者选择手术而不是药物。在技​​术创新方面，开发新分子标靶、改进给药系统、探索联合治疗等领域是业务成长的重大机会。市场充满活力，但受到高度竞争和监管障碍的限制，需要策略规划和持续创新才能保持竞争力并在全球市场上立足。

主要市场统计
基准年[2023] 80601万美元
预测年份 [2024] 89096万美元
预测年份 [2030] 16.7577 亿美元
复合年增长率（%） 11.02%

市场动态：揭示快速发展的甲状腺癌药物市场的关键市场洞察

供需的动态交互作用正在改变甲状腺癌药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球甲状腺癌盛行率不断上升
    • 越来越重视早期诊断和治疗
    • 私人组织增加癌症筛检项目
  • 市场限制因素
    • 与甲状腺癌治疗相关的副作用
  • 市场机会
    • 政府为提高癌症意识和采用报销政策所做的积极努力
    • 扩大个人化医疗和标靶治疗的潜力
  • 市场挑战
    • 严格的政府药品核准程序

波特五力：驾驭甲状腺癌药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对甲状腺癌药物市场的影响

外部宏观环境因素在塑造甲状腺癌治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解甲状腺癌治疗药物市场的竞争状况

对甲状腺癌治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

甲状腺癌治疗市场中的 FPNV 定位矩阵供应商绩效评估

FPNV定位矩阵是评估甲状腺癌药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了甲状腺癌治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对甲状腺癌治疗药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球甲状腺癌发生率增加
      • 注重早期诊断、早期治疗
      • 私人组织的增加增加了癌症筛检计划
    • 抑制因素
      • 与甲状腺癌治疗相关的副作用
    • 机会
      • 政府采取有利措施提高癌症意识并推出保险报销政策
      • 个人化医疗和标靶治疗的指数级潜力
    • 任务
      • 严格的政府药品核准程序
  • 市场区隔分析
    • 药物类型：快速采用标靶治疗，透过减少副作用与改善患者预后直接相关
    • 最终用户：先进设备促进了各医院甲状腺癌药物的获取
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类型分類的甲状腺癌治疗市场

  • 化疗药物
  • 荷尔蒙疗法药物
  • 免疫治疗药物
  • 标靶治疗

第七章 依管理方式分類的甲状腺癌治疗药物市场

  • 注射药物
  • 静脉注射药物
  • 口腔医学

第八章依疾病分期分類的甲状腺癌治疗药物市场

  • 晚期甲状腺癌
  • 甲状腺癌的早期阶段

第9章按癌症类型分類的甲状腺癌治疗药物市场

  • 未分化甲状腺癌
  • 滤泡性甲状腺癌
  • 甲状腺髓样癌
  • 甲状腺乳突癌

第10章甲状腺癌治疗市场：依最终用户分类

  • 医院
  • 肿瘤门诊
  • 调查机构

第十一章 美洲甲状腺癌药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太甲状腺癌药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲甲状腺癌药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准selpercatinib 用于治疗患有 RET 突变甲状腺癌的年轻患者，扩大了治疗选择
    • 工业宣布在甲状腺癌治疗上取得可喜进展
    • Rigel Pharmaceuticals 获得 Gavreto 在美国的权利，扩大甲状腺癌的治疗选择
  • 战略分析和建议

公司名单

  • Abbott Ltd.
  • Aprazer Healthcare Pvt Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • Biovista Inc.
  • Bristol Myers Squibb
  • Dr Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis Inc.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Healthcare Limited
  • Loxo Oncology Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • MSN Laboratories
  • Mylan NV
  • Natco Pharma Ltd.
  • Novartis AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vascular Biogenics Ltd.
Product Code: MRR-434CCDA052BE

The Thyroid Cancer Drugs Market was valued at USD 806.01 million in 2023, expected to reach USD 890.96 million in 2024, and is projected to grow at a CAGR of 11.02%, to USD 1,675.77 million by 2030.

The scope of the thyroid cancer drugs market involves pharmaceuticals specifically designed to treat thyroid cancer, including small molecule inhibitors, immunotherapies, radioactive iodine treatment, and thyroid hormone therapy. This sector is crucial for addressing unmet medical needs, as the rising incidence of thyroid cancer emphasizes the necessity for effective treatments. These drugs are applied primarily in clinical settings by healthcare professionals aiming to manage or cure different types of thyroid cancers such as papillary, follicular, medullary, and anaplastic. The end-use scope includes hospitals, oncology centers, and specialized clinics dedicated to cancer treatment. Key growth influencers in this market include advancements in precision medicine and targeted therapies, increasing R&D investments, as well as rising patient awareness and demand for effective treatment options. The emergence of biosimilars and the integration of AI in drug discovery represent potential opportunities, paving the way for more personalized medicine and cost-effective treatments. To capitalize on these opportunities, pharmaceutical companies should invest in robust R&D programs and strategic partnerships to accelerate drug development and streamline regulatory approvals. However, the market faces limitations such as high development costs, stringent regulatory frameworks, and potential side effects associated with thyroid cancer therapies. Additionally, competition from surgical treatment options poses challenges, as some patients opt for surgery over drug-based therapies. In terms of innovation, areas such as the development of novel molecular targets, improvements in drug delivery systems, and the exploration of combination therapies represent significant opportunities for business growth. The market is dynamic but constrained by high competition and regulatory hurdles, which necessitate strategic planning and continuous innovation to maintain competitiveness and secure a foothold in the global market.

KEY MARKET STATISTICS
Base Year [2023] USD 806.01 million
Estimated Year [2024] USD 890.96 million
Forecast Year [2030] USD 1,675.77 million
CAGR (%) 11.02%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Thyroid Cancer Drugs Market

The Thyroid Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of thyroid cancer cases across the globe
    • Increasing focus on early diagnosis and treatment
    • Rising private organizations increasing cancer screening programs
  • Market Restraints
    • Adverse side effects associated with thyroid cancer treatments
  • Market Opportunities
    • Favorable government initiatives promoting cancer awareness and introduction of reimbursement policies
    • Exponential potential for personalized medicine and targeted therapies
  • Market Challenges
    • Stringent government drug approval procedures

Porter's Five Forces: A Strategic Tool for Navigating the Thyroid Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Thyroid Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Thyroid Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Thyroid Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Thyroid Cancer Drugs Market

A detailed market share analysis in the Thyroid Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Thyroid Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Thyroid Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Thyroid Cancer Drugs Market

A strategic analysis of the Thyroid Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Thyroid Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Ltd., Aprazer Healthcare Pvt Ltd., AstraZeneca PLC, Bayer AG, Biovista Inc., Bristol Myers Squibb, Dr Reddy's Laboratories Ltd., Eisai Co., Ltd., Eli Lilly and Company, Exelixis Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Hetero Healthcare Limited, Loxo Oncology Inc., Lupin Limited, Merck & Co., Inc., MSN Laboratories, Mylan N.V., Natco Pharma Ltd., Novartis AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vascular Biogenics Ltd..

Market Segmentation & Coverage

This research report categorizes the Thyroid Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Chemotherapy Drugs, Hormone Therapy Drugs, Immunotherapy Drugs, and Targeted Therapy Drugs.
  • Based on Mode of Administration, market is studied across Injectable Drugs, Intravenous Drugs, and Oral Drugs.
  • Based on Stage of Disease, market is studied across Advanced-stage Thyroid Cancer and Early-stage Thyroid Cancer.
  • Based on Cancer Type, market is studied across Anaplastic Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer, and Papillary Thyroid Cancer.
  • Based on End User, market is studied across Hospitals, Oncology Clinics, and Research Organizations.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of thyroid cancer cases across the globe
      • 5.1.1.2. Increasing focus on early diagnosis and treatment
      • 5.1.1.3. Rising private organizations increasing cancer screening programs
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse side effects associated with thyroid cancer treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable government initiatives promoting cancer awareness and introduction of reimbursement policies
      • 5.1.3.2. Exponential potential for personalized medicine and targeted therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government drug approval procedures
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Proliferating adoption of the targeted therapy drugs directly translating to better patient outcomes with fewer adverse effects
    • 5.2.2. End User: Evolving utilization of thyroid cancer drugs across the hospitals owing to the advanced facilities
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Thyroid Cancer Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Chemotherapy Drugs
  • 6.3. Hormone Therapy Drugs
  • 6.4. Immunotherapy Drugs
  • 6.5. Targeted Therapy Drugs

7. Thyroid Cancer Drugs Market, by Mode of Administration

  • 7.1. Introduction
  • 7.2. Injectable Drugs
  • 7.3. Intravenous Drugs
  • 7.4. Oral Drugs

8. Thyroid Cancer Drugs Market, by Stage of Disease

  • 8.1. Introduction
  • 8.2. Advanced-stage Thyroid Cancer
  • 8.3. Early-stage Thyroid Cancer

9. Thyroid Cancer Drugs Market, by Cancer Type

  • 9.1. Introduction
  • 9.2. Anaplastic Thyroid Cancer
  • 9.3. Follicular Thyroid Cancer
  • 9.4. Medullary Thyroid Cancer
  • 9.5. Papillary Thyroid Cancer

10. Thyroid Cancer Drugs Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals
  • 10.3. Oncology Clinics
  • 10.4. Research Organizations

11. Americas Thyroid Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Thyroid Cancer Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Thyroid Cancer Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. FDA Approves Selpercatinib for Young Patients with RET-Altered Thyroid Cancer, Expanding Treatment Option
    • 14.3.2. ONO Pharmaceutical Unveils Promising Advances in Thyroid Cancer Treatment
    • 14.3.3. Rigel Pharmaceuticals Secures U.S. Rights to Gavreto, Enhancing Options for Thyroid Cancer Treatment
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Ltd.
  • 2. Aprazer Healthcare Pvt Ltd.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Biovista Inc.
  • 6. Bristol Myers Squibb
  • 7. Dr Reddy's Laboratories Ltd.
  • 8. Eisai Co., Ltd.
  • 9. Eli Lilly and Company
  • 10. Exelixis Inc.
  • 11. GlaxoSmithKline PLC
  • 12. Glenmark Pharmaceuticals Ltd.
  • 13. Hetero Healthcare Limited
  • 14. Loxo Oncology Inc.
  • 15. Lupin Limited
  • 16. Merck & Co., Inc.
  • 17. MSN Laboratories
  • 18. Mylan N.V.
  • 19. Natco Pharma Ltd.
  • 20. Novartis AG
  • 21. Sanofi S.A.
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Vascular Biogenics Ltd.

LIST OF FIGURES

  • FIGURE 1. THYROID CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. THYROID CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. THYROID CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THYROID CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THYROID CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INTRAVENOUS DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ADVANCED-STAGE THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY EARLY-STAGE THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. THYROID CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023